



mgc pharma 

Product Catalogue

A person wearing a white lab coat and blue gloves is using scissors to trim a plant in a tray. The background is a blurred green outdoor setting. The text is overlaid on the left side of the image.

Returning to
human knowledge
that has been
ignored by science
for centuries

mgc pharma 



INTRODUCTION

As the world moves into a new phase of medicines, returning to human knowledge that has been ignored by science for centuries, the horizon of treatments using phytocannabinoids is growing wider and wider.

MGC Pharmaceuticals is at the forefront of the shift – bringing together the scientific world of pharma with the holistic and long acknowledged benefits of phytocannabinoids to an ever growing window of indications.

The Cannabis plant contains more than one hundred phytocannabinoids; the two most well-known in today's world are cannabidiol (CBD) and tetrahydrocannabinol (THC).

MGC Pharma's core belief in creating a seamless Seed to Pharma pipeline is that every one of those phytocannabinoids has a value that has yet to be fully explored, researched in depth, or brought to patients via acceptable mediums. We are bridging that gap every day.

ABOUT MGC PHARMA

A complete Seed to Pharma pipeline.

mgc pharma 

MGC Pharmaceuticals (ASX:MXC, OTC:MGCLF) is a EU based Bio-Pharma company, creating a seamless pipeline of high quality, pharmaceutical grade products, taking advantage of the medical value of phytocannabinoids.

MGC Pharma is focused on the production of pharmaceutical products supported by ongoing research and development activities, as well as the production of Active Pharmaceutical Ingredient (API) of various cannabinoids, emerging from a self contained pipeline that runs from cultivation through extraction.

OUR VISION

MGC Pharma is positioned as a global leader in phytocannabinoid-based medicines within the biopharmaceuticals industry.

MGC Pharma's goal is to facilitate the transformation of phytocannabinoids into true medical product pipelines, and to provide breakthrough solutions for prevalent global health issues to improve the quality of patients' lives.

Active R&D and finding new ways to access patients are at the core of MGC Pharma's values and forward momentum.

By compounding more than one standardized Natural Active Ingredient, we are creating a controlled "Small" Entourage Effect, meeting regulatory requirements for standardized medicine while providing the therapeutic benefits of combining several natural compounds - creating greater harmony within the body and generating better patient outcomes.

By bringing together the most experienced and curious minds from around the world with the goal of targeting and providing formulations for the most pressing medical issues which can be addressed with phytocannabinoids today, MGC Pharma is ensuring patients reap the benefits of a full suite of phytocannabinoid treatments into the future.

The core of MGC Pharma's Seed to Pharma strategy is focused on medical research and development of the Company's pharmaceutical product pipeline, which provides raw materials and appropriately matched genetics to treat patients with a variety of diseases across the globe.



PHYTOTHERAPEUTICS

While MGC Pharma is developing indication specific formulations, we have available a range of products to allow medical professionals to prescribe as they see best suited for their patient. These products range from pure, whole plant CBD extract, through to a high-THC formulation.

Phytomedicine (see page 9) development can take years, but patients are suffering today. As a Bio-Pharma company, the first thought must always be of the patient, and there are solutions which are proven to significantly impact their wellness.

Based on our research, our scientific boards experience, and the company's understanding of global legislation, MGC Pharma has isolated formulations which have significant potential to treat the widest swath of indications.

MGC Pharma has implemented these products in our pipeline as immediate and accessible solutions to patients, as patient access is a main pillar of the company's activity, globally.

This agenda is supported by MGC Pharma's extensive experience in rollouts of medical Cannabis programs throughout the world.

These fully GMP compliant phytotherapeutic products are the result of the past twenty years of mixed global legalisation and medical regimes, the accompanying accrued data, and research. This provides a context for formulations with proven significant positive impact on patients with epilepsy, cancer, diabetes and end-stage renal disease, to name but a few of the current usages in countries such as Israel, Australia, Canada, the UK, the US, and more.

[Ask more about the applications and available references for the efficacy of Phytotherapeutics.](#)



PHYTOTHERAPEUTICS

Standardized cannabis preparations



MXP 100

CBD: **100 mg/ml**

Active ingredient:

Each 30ml bottle contains 3,000 mg of active ingredient.

Description:

100 mg per ml of CBD in MCT oil, delivered in an oral solution, with a purity level >98%.

Storage Requirement:

Room temperature below 25°C

Product shelf life:

6 months from date of manufacture



MXC 1:30

CBD: **100 mg/ml**

THC: **3 mg/ml**

Active ingredient:

Each 30ml bottle contains 3,090 mg of active ingredient.

Description:

A high-CBD blend, containing 100mg per ml of CBD and 3 mg/ml of THC, in MCT oil, delivered in an oral solution.

Storage Requirement:

Room temperature below 25°C

Product shelf life:

6 months from date of manufacture



MXC 1:1

CBD: **25 mg/ml**

THC: **25 mg/ml**

Active ingredient:

Each 30ml bottle contains 1,500 mg of active ingredient.

Description:

A 1:1 blend combining the therapeutic benefits of both CBD and THC, in MCT oil, delivered in an oral solution. 1:1 blends are a common starting point for medical practitioners.

Storage Requirement:

Room temperature below 25°C

Product shelf life:

6 months from date of manufacture



MXC 7:1

CBD: **3.6 mg/ml**

THC: **25 mg/ml**

Active ingredient:

Each 30ml bottle contains 825 mg of active ingredient.

Description:

A high-THC blend, containing 25mg per ml of THC, in MCT oil, delivered in an oral solution. Results in some psychoactivity while minimizing other side effect from THC.

Storage Requirement:

Room temperature below 25°C

Product shelf life:

6 months from date of manufacture



MXC 15:1

CBD: **1.7 mg/ml**

THC: **25 mg/ml**

Active ingredient:

Each 30ml bottle contains 801 mg of active ingredient.

Description:

25 mg per ml of THC, in MCT oil, delivered in an oral solution. While being the main psychoactive component, THC may help modulate neurotransmitters.

Storage Requirement:

Room temperature below 25°C

Product shelf life:

6 months from date of manufacture



White Label Services

MGC Pharma provides white label manufacturing, packing and distribution, of any formulation, as a service.

Our manufacturing and laboratory facilities are GMP certified, ensuring the highest quality of products.

See Page 13 for more information about our facilities and services.

PHYTOMEDICINES

MGC Pharma has built a unique Seed to Pharma pipeline that encompasses everything from cultivation & manufacturing, through clinical research, until the medication reaches the patient via a doctor and pharmacy.

Our ultimate goal has been to create products that are fully compliant with existing pharmaceutical regulations in every jurisdiction, with the only distinction being the presence of phytocannabinoids from the Cannabis plant.

From a doctor and patients point of view, they are considering a product which has been proven to be either as effective, or more effective, than their current medication, and the question of 'what is it made of' being no more applicable than it is to an antibiotic or anticoagulant.

From a formulation point of view, these products are created at the highest level of pharmaceutical formulation, fully GMP supervised and compliant, and are already being provided to patients as part of either clinical studies, observational studies or special access schemes in specific countries that allow them.

Our intention is to place our products on the shelves alongside every other available medication, and to shift the conversation from Cannabis to personalized medicine for the individual. Our desire is for patients to be given the ability to have fuller, healthier and happier lives. Cannabis holds within it elements that can facilitate this goal, and as such we are investing ourselves in researching, developing and creating products that will have that effect, globally.

MGC Pharma is focused on existing in the Pharma space by operating at the highest standards, providing the deepest levels of evidence and testing available, and educating and changing minds with results generated by the most important part of our company: the patients.

[Ask more about the applications and available references for the efficacy of Phytomedicines.](#)





CANNÉPIL™

Formulation of phytocannabinoids delivered as an oral solution to treat refractory epilepsy (drug resistant epilepsy).

Formulation:

Cannabidiol (CBD) 100 mg/ml
Delta-9-Tetrahydrocannabinol (THC) 5 mg/ml

Route of administration:

Oral

Format:

50 ml bottle with child protected graduated pipette

Storage Requirement:

Room temperature below 25°C

Product shelf life:

6 months from date of manufacture

COGNICANN

Formulation of phytocannabinoids delivered as an oral solution to treat dementia and Alzheimer's.

Formulation:

Delta-9-Tetrahydrocannabinol (THC) 25 mg/ml
Cannabidiol (CBD) 17 mg/ml

Route of administration:

Oral Spray

Format:

10 ml bottle with 2.5 mg cannabinoid metered dosage spray

Storage Requirement:

Room temperature below 25°C

Product shelf life:

6 months from date of manufacture

INCANN

Formulation of phytocannabinoids delivered as an oral solution to treat Crohn's and colitis.

Formulation:

Delta-9-Tetrahydrocannabinol (THC) 5 mg/capsule
Cannabidiol (CBD) 20 mg/capsule

Route of administration:

Capsules

Format:

30 slow release capsules with 25 mg cannabinoid per capsule

Storage Requirement:

Room temperature below 25°C

Product shelf life:

6 months from date of manufacture

TETRINOL

Formulation of phytocannabinoids delivered as an oral solution to treat cachexia in cancer and post cancer patients.

Formulation:

Delta-9-Tetrahydrocannabinol (THC) 16 mg/ml
Cannabidiol (CBD) 2 mg/ml

Route of administration:

Oral Spray

Format:

10 ml bottle with 2.5 mg cannabinoid metered dosage spray

Storage Requirement:

Room temperature below 25°C

Product shelf life:

6 months from date of manufacture

TOPICANN

Topical cream with phytocannabinoids for sensitive and irritated skin with anti inflammatory properties to treat mild conditions such as dermatitis (eczema), rosacea, seborrheic dermatitis and psoriasis.

Formulation:

Cannabidiol (CBD) 5 mg/ml + Natural extract

Route of administration:

Topical

Format:

100 ml topical cream

Storage Requirement:

Room temperature below 25°C

Product shelf life:

6 months from date of manufacture

CEPACANN

Formulation of phytocannabinoids delivered as an oral solution to treat cerebral palsy.

Formulation:

Cannabidiol (CBD) 100 mg/ml
Delta-9-Tetrahydrocannabinol (THC) 10 mg/ml

Route of administration:

Oral Spray

Format:

20 ml bottle with child protected graduated pipette

Storage Requirement:

Room temperature below 25°C

Product shelf life:

6 months from date of manufacture

FACILITIES & SERVICES



In order to maximize the value of our research into commercialization, MGC Pharma has centralized its main operations in Europe, while holding several operational branches in other strategic territories.





Medicines formulation

As a Bio-Pharma company, MGC Pharma holds an EU License to produce Non-Sterile schedule 2 medicines, in which falls cannabinoids, including the THC compound. This license is one of a few in the world that have the ability to produce and compound medicine based on phytocannabinoids.



Cultivation & Manufacturing

MGC Pharma's agenda is to control the entire product chain, achieving the company's core strategy of being a Seed to Pharma Bio-Pharma in order to provide cost effective medicine. To achieve this, MGC Pharma holds several cultivation & manufacturing sites and opportunities, globally.



API & Research products

Under its current license, MGC Pharma can provide manufacturing and formulation services with any and all API's, including but not limited to phytocannabinoids. With a global distribution network, MGC Pharma is able to provide API to research facilities and organisations seeking to implement phytocannabinoids into their product lines.



Technical resources

MGC Pharma facilities are GMP Class D non-sterile certified, with capabilities to compound API. This, along with their packaging facilities, means MGC Pharma can provide white label formulations.

Additionally, the MGC Pharma production site is certified for HACCP for Food and Food Supplement, to produce and develop Hemp based supplements, such as Hemp Proteins, CBD Capsules, Omega liquid gels, v-pens, etc. MGC Pharma provides white label production of such products.

mgc pharma 

www.mgcpharma.com.au

info@mgcpharma.com.au